(19)
(11) EP 3 849 572 A2

(12)

(88) Date of publication A3:
22.05.2020

(43) Date of publication:
21.07.2021 Bulletin 2021/29

(21) Application number: 19860890.3

(22) Date of filing: 10.09.2019
(51) International Patent Classification (IPC): 
A61K 35/17(2015.01)
A61K 39/44(2006.01)
C07K 16/24(2006.01)
C12N 5/0783(2010.01)
A61K 39/395(2006.01)
A61P 35/02(2006.01)
C07K 16/28(2006.01)
(86) International application number:
PCT/US2019/050494
(87) International publication number:
WO 2020/055932 (19.03.2020 Gazette 2020/12)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 10.09.2018 US 201862729043 P
02.10.2018 US 201816149346
02.10.2018 WO PCT/US2018/053933
29.11.2018 US 201816204220
15.01.2019 US 201916248762
22.02.2019 US 201916283694

(71) Applicant: Humanigen, Inc.
Burlingame, CA 94010 (US)

(72) Inventors:
  • DURRANT, Cameron
    Oxford, Florida 34484-2821 (US)
  • CHAPPELL, Dale
    Dolores, Colorado 81323 (US)

(74) Representative: Pearl Cohen Zedek Latzer Baratz UK LLP 
The Gridiron Building One Pancras Square
London N1C 4AG
London N1C 4AG (GB)

   


(54) METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST